PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20456216-2	2010	Prior to the United States Food and Drug Administration approval of the immunomodulatory agent, interferon-beta1b in 1993, no other drug had been shown to alter the course of the disease in a controlled study of MS. At present, there are five licenced disease-modifying agents in MS - interferon-beta1b, interferon-beta1a, glatiramer acetate, natalizumab and mitoxantrone.	Mitoxantrone	359-371	interferon beta 1	Homo sapiens	96-112	
19514518-6	2009	Interferon beta (IFN-beta), which is an immunomodulatory drug, is the only drug approved in Japan for treating MS; however, it is only partially effective or rather ineffective for treating patients with rapidly worsening or fulminant MS. Our pilot studies confirmed the benefits of mitoxantrone in Japanese patients with MS, and in this study, we review its potential appliciation for the treatment of MS by Japanese neurologists.	Mitoxantrone	283-295	interferon beta 1	Homo sapiens	0-15	
19514518-6	2009	Interferon beta (IFN-beta), which is an immunomodulatory drug, is the only drug approved in Japan for treating MS; however, it is only partially effective or rather ineffective for treating patients with rapidly worsening or fulminant MS. Our pilot studies confirmed the benefits of mitoxantrone in Japanese patients with MS, and in this study, we review its potential appliciation for the treatment of MS by Japanese neurologists.	Mitoxantrone	283-295	interferon beta 1	Homo sapiens	17-25	
15833373-1	2005	We assessed the action of mitoxantrone (MX) when given as rescue therapy in patients with relapsing-remitting (RR) multiple sclerosis (MS), whose disease activity worsens despite IFN-beta treatment.	Mitoxantrone	26-38	interferon beta 1	Homo sapiens	179-187	
15833373-0	2005	Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta.	Mitoxantrone	0-12	interferon beta 1	Homo sapiens	86-94	
14579493-6	2003	Interferon beta (Avonex, Rebif, Betaferon/Betaseron) and Glatirameracetate (Copaxone) offer effective therapeutic options for the long-term treatment of relapsing-remitting MS. With Mitoxantron (Ralenova) being recently approved by the EMEA for the treatment of secondary-progressive and progressive-relapsing MS an effective therapeutic option is now available also for this group of patients.	Mitoxantrone	182-193	interferon beta 1	Homo sapiens	0-15